|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 StephenW 于 2013-5-31 21:24 编辑
Simtuzumab, an Antifibrotic Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2) Enzyme, Is Safe and Well Tolerated in Patients With Liver Disease
|
|
| Reported by Jules Levin
EASL 2013 April Amsterdam
Andrew H. Talal1,2, Marlene Feron-Rigodon1, Jeannine Madere3, Xiaoru Wu3, G. Mani Subramanian3, Jeffrey D. Bornstein31Weill-Cornell Medical College, New York, NY, USA; 2SUNY-Buffalo, Buffalo, NY, USA; 3Gilead Sciences, Inc., Foster City, CA, USA 
|
|
|  | |
|
| | |
|
-
总评分: 现金 + 1
查看全部评分
|
发表于 2013-5-31 21:23
